Q2 FY26 results: Standalone loss Rs 28L, H1 consolidated profit Rs 1,115L
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sastasundar Ventures Q2 FY26 standalone net loss was Rs 27.98L vs Rs 31.90L loss YoY; H1 FY26 standalone loss Rs 38.93L vs Rs 54.05L profit last year. Consolidated Q2 PAT (after associate share) was a loss of Rs 1,845.93L; H1 FY26 swung to Rs 1,115.28L profit vs Rs 11,332.33L loss YoY, helped by absence of large prior-year exceptional items. Revenue from operations grew about 10% YoY to Rs 59,974.88L. Exceptional item of Rs 16.61L booked for Genu Path Labs PPE impairment. Auditor flagged material going concern uncertainty at step-down subsidiary Genu Path Labs (net loss Rs 186.20L, net worth eroded). Material subsidiary SHBL completed buyback of about Rs 10,000L.
Standalone losses persist but consolidated turned profitable on base effect. Going concern flag at Genu Path Labs and healthcare segment losses are red flags.